RNA/DNA Polymerase

Items 101-124 of 124

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. HCMV DNA Polymerase Alpha Inhibitor

    Naphthol AS-BS is a selective inhibitor of human cytomegalovirus (HCMV) DNA polymerase alpha, exhibiting an IC50 of 12 μM. This compound is significant for research into viral infections, particularly in understanding the mechanisms of HCMV replication and potential therapeutic interventions. Its inhibitory properties make it a valuable tool in virology studies and drug development efforts targeting HCMV.
  2. HCV NS5B RNA-dependent RNA Polymerase Inhibitor

    HCV-IN-50 is a potent inhibitor of HCV NS5B RNA-dependent RNA polymerase, demonstrating a selective competitive mechanism with an IC50 of 0.3 μM for the NS5B △C21 enzyme compared to the △C55 variant. This compound exhibits significant antiviral activity, effectively inhibiting the replication of Hepatitis C virus subgenomic replicons, including mutant strains. HCV-IN-50 is valuable for research applications focused on HCV replication mechanisms and antiviral drug development.
  3. Antibacterial Agent, RNA Polymerase Inhibitor

    2,5-Di-tert-butyl-1,4-benzoquinone serves as a potent antibacterial agent and an effective RNA polymerase inhibitor. Isolated from the marine species Streptomyces sp. VITVSK1, this compound exhibits significant antibacterial activity, providing critical insights into combating emerging antibacterial resistance. Its ability to inhibit RNA polymerase further supports its value in research applications focused on microbial gene expression and antibiotic mechanisms.
  4. DNA Polymerases α/δ/ε Inhibitor

    PMEG is an inhibitor of nuclear DNA polymerases α, δ, and ε, leading to DNA chain termination and suppression of DNA synthesis, which induces cytotoxicity in rapidly dividing cells. As an acyclic nucleotide phosphonate, PMEG is converted within cells to its active form, PMEG diphosphate. This compound demonstrates efficacy against leukemia and melanoma in rodent models and exhibits antiviral activity against various DNA viruses, including murine and human cytomegalovirus. PMEG serves as a valuable reagent for research into non-Hodgkin's lymphoma and related areas of study.
  5. RSV Polymerase inhibitor

    RSV L-protein-IN-3 is an inhibitor of respiratory syncytial virus (RSV) polymerase, displaying an IC50 value of 10.4 μM and an EC50 value of 2.1 μM against RSV. It demonstrates reduced cytotoxicity compared to the clinical agent Ribavirin, making it a suitable candidate for further research into treating RSV infections. This compound is valuable for studies focusing on antiviral mechanisms and drug development targeting RSV.
  6. RSV Polymerase Inhibitor

    RSV L-protein-IN-4 is a noncompetitive inhibitor of the respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 value of 0.88 μM. This compound demonstrates significant antiviral activity against various RSV strains, with an EC50 of 0.25 μM. RSV L-protein-IN-4 is essential for research into antiviral therapies targeting RSV infections.
  7. RSV Polymerase Inhibitor

    RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms.
  8. RNA-dependent RNA Polymerase Inhibitor

    BPR3P0128 is a non-nucleoside inhibitor of RNA-dependent RNA polymerase (RdRp), demonstrating potent antiviral activity against various SARS-CoV-2 variants. It exhibits EC50 values of 0.62 μM for SARS-CoV-2 and 0.14 μM for HCoV-229E, effectively inhibiting virus replication within the submicromolar range. Additionally, BPR3P0128 shows synergistic effects when used in combination with Remdesivir, making it a promising candidate for further antiviral research against coronaviruses.
  9. HSV Polymerases Inhibitor

    PNU-183792 is a potent inhibitor of herpes simplex virus (HSV) polymerases, classified as a 4-oxo-dihydroquinoline. It demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 0.69 μM for human cytomegalovirus (HCM), 0.37 μM for varicella zoster virus, and 0.58 μM for HSV polymerases. Importantly, PNU-183792 operates selectively, showing no activity against human α, γ, or δ polymerases. Additionally, it exhibits inhibitory effects on simian varicella virus (SVV), murine cytomegalovirus (MCMV), and rat cytomegalovirus (RCMV), making it a valuable tool for antiviral research.
  10. Ns5b Polymerase Inhibitor

    Anti-infective agent 10 is an NS5B polymerase inhibitor designed for research into hepatitis C virus (HCV) infections. This compound effectively disrupts the viral replication process, making it a valuable tool for studying HCV biology and developing antiviral therapies. Its applications extend to evaluating drug resistance mechanisms and supporting drug discovery efforts in combating HCV.
  11. Ns5b Polymerase Inhibitor

    HCV NS5B polymerase-IN-2 is an inhibitor targeting the NS5B polymerase of the hepatitis C virus (HCV). This compound demonstrates significant antiviral activity against HCV replication, making it a valuable tool for the investigation of hepatitis C viral infections and the development of therapeutic strategies. Its efficacy in inhibiting NS5B polymerase highlights its potential role in studying HCV dynamics and drug resistance.
  12. HCV NS5B Polymerase Inhibitor

    BI 207524 is a selective non-nucleoside inhibitor of HCV NS5B polymerase, specifically targeting thumb pocket 1. This compound demonstrates antiviral activity against hepatitis C virus (HCV). BI 207524 is applicable in research focused on HCV infection and the mechanisms of antiviral response.
  13. HCV Polymerase Inhibitor

    HCVP-IN-1 is a potent inhibitor of hepatitis C viral polymerase (HCVP). This compound effectively disrupts viral replication, making it a valuable tool for studying the dynamics of hepatitis C virus infection. HCVP-IN-1 is particularly relevant in research focused on developing antiviral therapies and understanding the mechanisms of HCV-related diseases.
  14. Chikungunya Virus Polymerase Inhibitor

    GAP-1173149 is a selective inhibitor of the Chikungunya virus (CHIKV) polymerase, specifically targeting the nsP4 RNA-dependent RNA polymerase. This compound demonstrates potent antiviral activity by hindering viral RNA replication, making it a valuable tool for studying CHIKV biology and developing antiviral strategies. Its application is particularly relevant in research focused on emerging viral threats and potential therapeutic interventions for Chikungunya virus infections.
  15. Viral DNA Polymerases Inhibitor

    Cidofovir diphosphate is a potent inhibitor of viral DNA polymerases, primarily targeting human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), and herpes simplex virus type 2 (HSV-2). With Ki values of 6.6 μM, 0.86 μM, and 1.4 μM for these polymers, respectively, it demonstrates selective antiviral activity. This compound is instrumental in research focusing on antiviral drug development and elucidating the mechanisms underlying viral DNA replication.
  16. Polymerase Inhibitor

    T-1105 is a novel broad-spectrum viral polymerase inhibitor that acts by being converted into a ribonucleoside triphosphate (RTP) metabolite. This compound demonstrates antiviral activity against multiple RNA viruses by inhibiting their polymerases. T-1105 is particularly significant in studies aimed at understanding viral replication and developing antiviral strategies. Its mechanism of action highlights its potential applications in viral pathogenesis research and therapeutic interventions.
  17. HCV NS5B Polymerase Inhibitor

    MB-11362 is a potent, orally active inhibitor of the hepatitis C virus (HCV) NS5B polymerase, functioning as a 4′-azidouridine triphosphate prodrug. Upon oral administration, MB-11362 is converted to its active form, 4′-azidouridine triphosphate, which effectively disrupts viral RNA synthesis. This compound is valuable for research focusing on HCV infection and understanding the mechanisms of antiviral therapies targeting RNA polymerases.
  18. HCV RNA Polymerase Inhibitor

    BILB 1941 is a potent nonnucleoside inhibitor targeting the hepatitis C virus (HCV) RNA polymerase. It demonstrates significant antiviral activity in vitro, making it a valuable tool for research applications related to HCV replication and drug development strategies against hepatitis C.
  19. NS5B Polymerase Inhibitor

    ABT-072 potassium trihydrate is a potent non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase. It demonstrates significant antiviral activity, exhibiting EC50 values of 1 nM against HCV genotype 1a and 0.3 nM against genotype 1b. This compound is primarily utilized in research focused on HCV replication and the development of antiviral therapies.
  20. HCV NS5B Polymerase Inhibitor

    MK3281 is a non-nucleoside inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. It demonstrates significant antiviral activity, with an EC50 of 28 nM for genotype 1a. This compound is utilized in research focused on antiviral drug development and understanding HCV replication mechanisms.
  21. NS5B Polymerase Inhibitor

    PSI-353661 is a purine nucleotide inhibitor targeting the NS5B polymerase of Hepatitis C Virus (HCV). It demonstrates potent antiviral activity with EC90 values of 8 nM for wild-type HCV and 11 nM for the S282T resistant strain. Additionally, PSI-353661 achieves elevated levels of its active triphosphate form in primary human hepatocytes, making it a valuable tool for studying HCV replication and resistance mechanisms.
  22. HCV NS5B Polymerase Inhibitor

    HCV NS5B polymerase-IN-3 is a potent inhibitor of the hepatitis C virus (HCV) NS5B polymerase, demonstrating significant antiviral activity. In the Huh7 replicon cell line, it exhibits an EC50 value of 0.23 μM while maintaining a favorable cytotoxicity profile. This compound is relevant for research applications focused on HCV replication and drug development strategies targeting hepatitis C.
  23. HCV Polymerase Inhibitor

    VCH-916 free base is a non-nucleoside inhibitor targeting the NS5B polymerase of Hepatitis C virus (HCV). This compound demonstrates potent antiviral activity, making it a valuable tool for research on HCV replication. It is primarily utilized in studies focused on developing effective treatments for Hepatitis C and understanding the viral mechanisms of polymerase function.
  24. DNA Polymerases Substrate

    Troxacitabine triphosphate (TRX-TP) serves as a substrate for DNA polymerases, specifically targeting replicative and repair enzymes. This compound demonstrates key biological activity by facilitating DNA synthesis and repair processes in vitro. It is valuable for research applications that involve the study of nucleotide incorporation and polymerase activity, providing insights into DNA replication and repair mechanisms.

Items 101-124 of 124

Page
per page
Set Descending Direction